Skip to NavigationSkip to content

Michael Moore, chairman, Oxford BioTherapeutics

Published on: 11/01/10

Oxford BioTherapeutics (OBT) has appointed Dr Michael Moore non-executive chairman.

He joins the company following five years spent at UK biotech Piramed, where he was chief executive until its 2008 acquisition by Roche.

Prior to that he was chief scientific officer and research director at Xenova and has previously held senior academic positions at the Paterson Institute for Cancer Research, Christie Hospital, Manchester, UK and the Brunel Institute of Cancer Genetics and Pharmacogenomics, where he is still professor associate.

Dr Moore commented: “I am delighted to join Oxford BioTherapeutics at this exciting time in the company’s development. I have been highly impressed by OBT’s scientific and commercial approach and am very pleased to join the other distinguished members of the OBT Board and management, as we work together to set the strategic framework for the company’s continued growth and success.”

OBT recently recruited a number of other senior industry leaders in the biologics field, including new chief operating officer Jim Cornett and chief scientific officer Mike Gresser.

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches